Publications by authors named "Srihari Gopal"

Claim this Profile
C
Correction: Pharmacokinetic Characteristics of Long‑Acting Injectable Antipsychotics for Schizophrenia: An Overview.
Christoph U Correll, Edward Kim, Jennifer Kern Sliwa, Wayne Hamm, Srihari Gopal

CNS Drugs· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I).
Huybrecht T'jollyn, Alberto Russu, Raja Venkatasubramanian, Srihari Gopal, Partha Nandy

Eur J Drug Metab Pharmacokinet· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II).
Huybrecht T'jollyn, Raja Venkatasubramanian, Martine Neyens, Srihari Gopal, Alberto Russu

Eur J Drug Metab Pharmacokinet· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study.
Ute Richarz, John Han, Ya-Mei Bai, Eric Yu-Hai Chen, Young Chul Chung, Venu Gopal Jhanwar, Srihari Gopal

Medicine (Baltimore)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study.
Cesar Giron-Hernandez, Joong Hee Han, Roberta Alberio, Arun Singh, Maria Paz García-Portilla, Srihari Gopal

Neuropsychiatr Dis Treat· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia.
Ruth Milz, Carmela Benson, Karl Knight, Jose Antunes, Dean Najarian, Srihari Gopal

Neuropsychiatr Dis Treat· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections.
Ibrahim Turkoz, Mehmet Daskiran, H Lynn Starr, Dean Najarian, Oliver Lopena, Srihari Gopal

Neuropsychiatr Dis Treat· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping genomic loci implicates genes and synaptic biology in schizophrenia.
Vassily Trubetskoy, Antonio F Pardiñas, Ting Qi, Georgia Panagiotaropoulou, Swapnil Awasthi, Srihari Gopal

Nature· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.
Dean Najarian, Panna Sanga, Steven Wang, Pilar Lim, Arun Singh, Srihari Gopal

Int J Neuropsychopharmacol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis.
Gang Li, Alexander Keenan, Mehmet Daskiran, Maju Mathews, Isaac Nuamah, Srihari Gopal

Patient Prefer Adherence· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate.
Rebekka Lencer, Maria Paz Garcia-Portilla, Paul Bergmans, Srihari Gopal, Maju Mathews

Compr Psychiatry· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining "Adequately Treated": A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate.
Amy O'Donnell, Sanjai Rao, Ibrahim Turkoz, Srihari Gopal, Edward Kim

Neuropsychiatr Dis Treat· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.
Christoph U Correll, Edward Kim, Jennifer Kern Sliwa, Wayne Hamm, Srihari Gopal

CNS Drugs· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes.
Katalin Pungor, Vasilis P Bozikas, Robin Emsley, Pierre-Michel Llorca, Srihari Gopal

Ther Adv Psychopharmacol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia.
Martin Lambert, Pedro Sanchez, Paul Bergmans, Srihari Gopal, Maju Mathews

Neuropsychiatr Dis Treat· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire.
Clifton Blackwood, Panna Sanga, Isaac Nuamah, Alexander Keenan, Arun Singh, Srihari Gopal

Patient Prefer Adherence· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies.
Maju Mathews, Srihari Gopal, Arun Singh, Isaac Nuamah, Katalin Pungor

Neuropsychiatr Dis Treat· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations.
Alberto Russu, Adam Savitz, Maju Mathews, Srihari Gopal, Yu Feng

J Clin Psychopharmacol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study.
Srihari Gopal, Jagadish Gogate, Katalin Pungor, Edward Kim, Arun Singh

Neuropsychiatr Dis Treat· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Paliperidone Palmitate (Once-Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia.
Hiroko Shimizu, Martine Neyens, Marc De Meulder, Srihari Gopal, Yuko Tsukamoto

Clin Pharmacol Drug Dev· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies.
Adam J Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Maju Mathews

Braz J Psychiatry· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: A Database Report and Case Study.
John M Kane, Christoph U Correll, Nicholas Delva, Srihari Gopal, Adam Savitz

J Clin Psychopharmacol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia.
Maju Mathews, Srihari Gopal, Isaac Nuamah, Ludger Hargarter, Adam J Savitz

Neuropsychiatr Dis Treat· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population.
Adam J Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Paulien Ravenstijn

Neuropsychiatr Dis Treat· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis